药品详细
Acyclovir(阿昔洛韦)
化学结构式图
中文名
阿昔洛韦
英文名
Acyclovir
分子式
C8H11N5O3
化学名
2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-3H-purin-6-one
分子量
Average: 225.2046
Monoisotopic: 225.086189243
Monoisotopic: 225.086189243
CAS号
59277-89-3
ATC分类
D06B 未知;J05A Direct acting antivirals;S01A 抗感染药;J05A Direct acting antivirals
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍
A guanosine analog antiviral drug that acts as an antimetabolite. Acyclovir is used for the treatment of herpes simplex virus infections, varicella zoster (chickenpox) and herpes zoster (shingles).
生产厂家
- Abbott laboratories
- Actavis elizabeth llc
- Actavis mid atlantic llc
- Apotex inc etobicoke site
- Apothecon inc div bristol myers squibb
- App pharmaceuticals llc
- Baxter healthcare corp anesthesia and critical care
- Bedford laboratories div ben venue laboratories inc
- Belcher pharmaceuticals inc
- Carlsbad technology inc
- Dava pharmaceuticals inc
- Genpharm inc
- Glaxosmithkline
- Hi tech pharmacal co inc
- Hospira inc
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Lek pharmaceutical and chemical co dd
- Mylan laboratories inc
- Mylan pharmaceuticals inc
- Ranbaxy laboratories ltd
- Roxane laboratories inc
- Stason industrial corp
- Teva parenteral medicines inc
- Teva pharmaceuticals usa
- Teva pharmaceuticals usa inc
- Watson laboratories inc
封装厂家
- Actavis Group
- Advanced Pharmaceutical Services Inc.
- Amerisource Health Services Corp.
- Amneal Pharmaceuticals
- Apotex Inc.
- Apotheca Inc.
- Apothecary Shop Wholesale
- APP Pharmaceuticals
- AQ Pharmaceuticals Inc.
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- Bedford Labs
- Ben Venue Laboratories Inc.
- Bryant Ranch Prepack
- BTA Pharmaceuticals
- Cardinal Health
- Carlsbad Technology Inc.
- Comprehensive Consultant Services Inc.
- Corepharma LLC
- DAVA Pharmaceuticals
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- DSM Corp.
- East Coast Medical Network Inc.
- Eczacibasi Health Products Co.
- GlaxoSmithKline Inc.
- Goldline Laboratories Inc.
- H.J. Harkins Co. Inc.
- Heritage Pharmaceuticals
- Hi Tech Pharmacal Co. Inc.
- Hospira Inc.
- Ivax Pharmaceuticals
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Liberty Pharmaceuticals
- Major Pharmaceuticals
- Mckesson Corp.
- Medvantx Inc.
- Meridian Medical Technologies Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Neuman Distributors Inc.
- Novopharm Ltd.
- Nucare Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- Patheon Inc.
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmedix
- Pharmpak Inc.
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Ranbaxy Laboratories
- Rebel Distributors Corp.
- Redpharm Drug
- Remedy Repack
- Resource Optimization and Innovation LLC
- Roxane Labs
- Southwood Pharmaceuticals
- St Mary's Medical Park Pharmacy
- Stason Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- Watson Pharmaceuticals
- Xactdose Inc.
- Yung Shin Pharmaceutical Industry Ltd.
参考
Synthesis Reference | Not Available |
General Reference |
|
剂型
规格
化合物类型
Type | small molecule |
Classes |
|
Substructures |
|
适应症
药理
Indication | For the treatment and management of herpes zoster (shingles), genital herpes, and chickenpox. | ||||||||
Pharmacodynamics | Aciclovir (INN) or acyclovir (USAN, former BAN) is a synthetic deoxyguanosine analog and it is the prototype antiviral agent that is activated by viral thymidine kinase. The selective activity of aciclovir is due to its affinity for the thymidine kinase enzyme encoded by HSV and VZV. EC50 value of acyclovir against clinical herpes virus isolates was 1.3 μM (range: < 0.56 to 3.3 μM). | ||||||||
Mechanism of action | Viral (HSV-1, HSV-2 and VZV) thymidine kinase converts aciclovir to the aciclovir monophosphate, which is then converted to the diphosphate by cellular guanylate kinase, and finally to the triphosphate by phosphoglycerate kinase, phosphoenolpyruvate carboxykinase, and pyruvate kinase. Aciclovir triphosphate competitively inhibits viral DNA polymerase and competes with the natural deoxyguanosine triphosphate, for incorporation into viral DNA. Once incorporated, aciclovir triphosphate inhibits DNA synthesis by acting as a chain terminator. One may consider aciclovir to be a prodrug as it is metabolized to more active compounds. Aciclovir is selective and low in cytotoxicity as the cellular thymidine kinase of normal, uninfected cells does not use aciclovir effectively as a substrate. | ||||||||
Absorption | The oral bioavailability is 10% to 20%, and decreases with increasing dose. Food does not affect the absorption of acyclovir. The following are the pharmacokinetic parameters for 50 mg buccal tablet, Sitavig, in the saliva: AUC 0 - 24 hours = 2900±2400 mcg.h/mL; Cmax = 440±241 mcg/mL; Tmax = 7.95 ± 4.08 hours. | ||||||||
Volume of distribution | Not Available | ||||||||
Protein binding | 9%-33% | ||||||||
Metabolism |
Hepatic, Acyclovir is metabolized to 9-[(carboxymethoxy)methyl]guanine (CMMG) and 8 hydroxy-acyclovir (8-OH-ACV) by oxidation and hydroxylation. It is suggested in studies that acyclovir is first metabolized to acyclovir aldehyde by alcohol dehydrogenase and then converted to CMMG. The build up of acyclovir aldehyde may be the cause of acyclovir-induced nephrotoxicity in the absence of crystalluria.
Important The metabolism module of DrugBank is currently in beta. Questions or suggestions? Please contact us.
|
||||||||
Route of elimination | Primarily excreted unchanged by the kidneys via active tubular secretion. | ||||||||
Half life | 2.5-3.3 hours | ||||||||
Clearance | Not Available | ||||||||
Toxicity | Aciclovir may cause nephrotoxicity (crystallization of aciclovir within renal tubules, elevation of serum creatinine, transient), and neurotoxicity (coma, hallucinations, lethargy, seizures, tremors). Nephrotoxicity and neurotoxicity usually resolve after cessation of aciclovir therapy. However, there is no well-defined relationship between aciclovir concentrations in the blood and these adverse effects. | ||||||||
Affected organisms |
|
||||||||
Pathways | Not Available |
理化性质
Properties | |||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
State | solid | ||||||||||||||||||||||||||||||||||||||||||
Experimental Properties |
|
||||||||||||||||||||||||||||||||||||||||||
Predicted Properties |
|
药物相互作用
Drug | Interaction |
---|---|
Aminophylline | Acyclovir increases the effect and toxicity of theophylline |
Dyphylline | Acyclovir increases the effect and toxicity of dyphylline. |
Oxtriphylline | Aciclovir may increase the effect and toxicity of oxtriphylline. |
Theophylline | Acyclovir may increase the effect and toxicity of theophylline. |
食物相互作用
- Increase liquid intake.
- Take without regard to meals.